Insulin glargine is a synthetic long-acting insulin analogue, produced through recombinant DNA technology. It belongs to the chemical class of insulin analogues and is designed to mimic the basal insulin secretion of the pancreas. Insulin glargine is available under various brand names, including Lantus, Toujeo, and Basaglar. Researchers have focused on its use in managing diabetes mellitus, particularly in providing a stable basal insulin level. The primary physiological role of insulin glargine is to regulate glucose metabolism by facilitating cellular glucose uptake, thereby lowering blood glucose levels. It is primarily used in the treatment of both type 1 and type 2 diabetes mellitus, where it helps maintain glycemic control by providing a consistent insulin level without pronounced peaks. Insulin glargine acts by binding to the insulin receptor, triggering a cascade of events that promote glucose uptake in muscle and fat tissues and inhibit hepatic glucose production. This mechanism of action is similar to endogenous insulin, but insulin glargine is designed to be released slowly over 24 hours, providing a steady insulin level. Pharmacokinetically, insulin glargine has a prolonged duration of action with no significant peak, and its time-action profile is relatively constant. It is administered subcutaneously, and its bioavailability and metabolism can vary among individuals. Clinically, insulin glargine is used as a basal insulin in diabetes management and is approved for use in adults and children with type 1 diabetes and adults with type 2 diabetes. It is well-tolerated and associated with a lower risk of hypoglycemia compared to some other insulin formulations. Regulatory agencies have approved insulin glargine for medical use, highlighting its importance in diabetes care.